IGC Pharma Inc. (NYSE American: IGC) has announced new preclinical data on TGR-63, its investigational small-molecule candidate for Alzheimer's disease. The results demonstrate that TGR-63 inhibits both beta-amyloid and tau protein aggregation, addressing two key pathological features of Alzheimer's. In vitro assays showed that TGR-63 suppresses tau fibril formation at micromolar concentrations, and previous findings indicated its effectiveness in disrupting beta-amyloid plaque aggregation. Serum stability studies confirmed that TGR-63 maintains its structural integrity under physiological conditions and remains detectable in serum samples up to 24 hours post-administration. These preclinical findings have been presented by the company, and further development of TGR-63 is planned to advance it as a potential disease-modifying therapy for Alzheimer's disease.